


IN THE CLAIMS:

The following listing replaces all prior listings and versions of the claims. Any subject matter deleted from a claim or any claims cancelled, is effected without prejudice.

1-14. Canceled.

15. (Currently Amended) A method of ~~treating a disease or medical condition in a mammal, which disease or medical condition responds to inhibition or reduction of angiogenesis, wherein the disease or medical condition is selected from rheumatoid arthritis, inflammatory disorder, macular degeneration, psoriasis, retinopathy, preneoplastic lesions, and hyperplasia, inhibiting or~~ reducing VEGF production in a mammal comprising administering to said mammal an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof:



I

wherein:

A is selected from the group consisting of the group members C₁₋₁₀-alkylene, C₂₋₁₀-alkenylene, and C₂₋₁₀-alkynylene, which group members may be optionally substituted by one, two or three groups independently selected from C₁₋₃-alkyl, fluoro, chioro, and bromo;

R¹ is selected from hydrogen, C₁₋₆-alkyl, fluoro, chloro, bromo, and perfluoro-C₁₋₃-alkyl;

R² is selected from hydrogen, C₁₋₆-alkyl, and C₂₋₆-alkenyl; and

R³ is selected from the group consisting of the group members C₁₋₆-alkyl, (C₅₋₈-cycloalkyl)-C₁₋₆-alkyl, (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, C₁₋₆-alkyl (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, and C₁₋₅-alkylcarbonyl (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, which group members may be optionally substituted by one, two or three

groups independently selected from C₁₋₆-alkyl, fluoro, chloro, bromo, oxo, perfluoro-C₁₋₃-alkyl, aryl, arylcarbonyl, heteroaryl, heteroarylcarbonyl, C₅₋₈-cycloalkyl and C₅₋₈-heterocyclyl.

16. (Previously Presented) The method of claim 15, wherein A is selected from ethylene, n-propylene, i-propylene, n-butylene, ethenylene, 1-propenylene, 1-butenylene, 2-butenylene, and ethynylene.

17. (Previously Presented) The method of claim 15, wherein R¹ is selected from hydrogen, methyl, ethyl, n-propyl, fluoro, and trifluoromethyl.

18. (Previously Presented) The method of claim 15, wherein R² is selected from hydrogen, methyl, ethyl, n-propyl, and ethenyl.

19. (Previously Presented) The method of claim 15, wherein R³ is selected from the group consisting of cyclopentyl-C₁₋₆-alkyl, cyclohexyl-C₁₋₆-alkyl, pyrrolidinyl-C₁₋₆-alkyl, piperidinyl-C₁₋₆-alkyl, C₁₋₆-alkyl-piperidinyl-C₁₋₆-alkyl, C₁₋₅-alkylcarbonyl piperidinyl-C₁₋₆-alkyl, piperazinyl-C₁₋₆-alkyl, C₁₋₆-alkyl-piperazinyl-C₁₋₆-alkyl, C₁₋₅-alkylcarbonyl-piperazinyl-C₁₋₆-alkyl, and morpholinyl-C₁₋₆-alkyl, which members may be optionally substituted by one, two or three groups independently selected from C₁₋₆-alkyl, fluoro, chloro, bromo, oxo, perfluoro-C₁₋₃-alkyl, aryl, arylcarbonyl, heteroaryl, C₅₋₈-cycloalkyl, and C₅₋₈-heterocyclyl.

20. (Previously Presented) The method of claim 15, wherein R³ is selected from the group consisting of:

cyclohexyl-C₁₋₆-alkyl, piperidinyl-C₁₋₆-alkyl, C₁₋₆-alkyl piperidinyl-C₁₋₆-alkyl, C₁₋₅-alkylcarbonyl-piperidinyl-C₁₋₆-alkyl, piperazinyl-C₁₋₆-alkyl, C₁₋₆-alkyl-piperazinyl-C₁₋₆-alkyl, C₁₋₅-alkylcarbonyl-piperazinyl-C₁₋₆-alkyl, which members may be optionally substituted by one, two or three groups independently selected from butyl, pentyl, hexyl, fluoro, oxo, phenyl, biphenyl, benzyl, pyridyl, pyrrolyl, benzoyl, thiophenyl; furyl, cyclopentyl, cyclohexyl, and piperidinyl.

21. (Previously Presented) The method of claim 15, wherein R³ is selected from the group consisting of.

(1-acetyl-piperidin-4-yl)-butyl,
(1-diphenylacetyl-piperidin-4-yl)-butyl,
(1- (3,3 -diphenylpropionyl)-piperidin-4-yl)butyl,
(1-benzoyl-piperidin-4-yl)-ethyl,
(1-benzoyl-piperidin-4-yl)-propyl,
(1-benzoyl-piperidin-4-yl)-butyl,
(1-benzoyl-piperidin-4-yl)-pentyl,
(1-benzoyl-piperidin-4-yl)-hexyl,
(1-benzylpiperidin-4-yl)-butyl,
(1-diphenylmethyl-piperidin-4-yl)-methyl,
(1-diphenylmethyl-piperidin-4-yl)-ethyl,
(1-diphenylmethyl-piperidin-4-yl)-propyl,
(1-diphenylmethyl-piperidin-4-yl)-butyl,
(1-diphenylmethyl-piperidin-4-yl)-pentyl,
(1-diphenylmethyl-piperidin-4-yl)-hexyl,
(4-phenyl-piperidin-1-yl)-butyl,
(4, 4-diphenyl-piperidin-1-yl)-butyl,
(1-benzoyl-2,6-dioxo-piperidin-4-yl)-butyl,
(2, 6-dioxo-3-phenyl-piperidin-1-yl)-butyl,
(2, 6-dioxo-4-phenyl-piperidin-1-yl)-butyl,
(4-phenyl-piperazin-1-yl)-butyl,
(4-phenyl-piperazin-1-yl)-pentyl,
(4-phenyl-piperazin-1-yl)-hexyl,
(4-diphenylacetyl-piperazin-1-yl)-butyl,
(4-benzoylpiperazin-1-yl)-butyl, and
(4-benzyl-2,6-dioxo-piperazin-1-yl)-butyl.

22. (Previously Presented) The method of claim 15, wherein the compound of Formula I is selected from the group consisting of:

N-[4-(1-acetyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide,
[4-(1-acetyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,
N-[4-(1-diphenylacetyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,
N-(4-(1-diphenylacetyl-piperidin-4-yl)-butyl)-3-(pyridin-3-yl)-propionamide,
N-(4-[1-(3,3-diphenylpropionyl)-piperidin-4-yl]-butyl)-3-(pyridin-3-yl)-acrylamide
N-[3-(1-benzoyl-piperidin-4-yl)-propyl]-3-(pyridin-3-yl)-propionamide,
N-[4-(1-benzoyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide,
N-[6-(1-benzoyl-piperidin-4-yl)-hexyl]-3-(pyridin-3-yl)-propionamide,
N-(2-[1-benzoyl-piperidin-4-yl)-ethyl]-3-(pyridin-3-yl)-acrylamide,
N-[4-(1-benzoyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,
N-[6-(1-benzoyl-piperidin-4-yl)-hexyl]-3-(pyridin-3-yl)-acrylamide,
N-[4-(1-benzoyl-piperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide,
N-[4-(4-benzoyl-piperidin-1-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,
N-[4-(4-benzoyl-piperidin-1-yl)-butyl]-3-(pyridin-3-yl)-propionamide,
N-[4-(1-benzylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-3-(2 fluoropyridin-3-yl)-propionamide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-3-(5 fluoropyridin-3-yl)-propionamide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-2-fluoro-3-(pyridin-3-yl)-
propionamide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-2,2-difluoro-3-(pyridin-3-yl)-
propionamide,
N-[5-(1-diphenylmethyl-piperidin-4-yl)-pentyl]-3-(pyridin-3-yl)-propionamide,
N-[6-(1-diphenylmethyl-piperidin-4-yl)-hexyl]-3-(pyridin-3-yl)-propionamide,
N-[2-(1-diphenylmethyl-piperidin-4-yl)-ethyl]-5-pyridin-3-yl)-pentanoic acid amide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-propionamide,
N-[4-(1-diphenylmethyl-piperidin-4-yl)-butyl]-5-(pyridin-3-yl)-pentanoic acid amide,
N-[2-(1-diphenylmethylpiperidin-4-yl)-ethyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid
amide,
N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid

amide,

N- [5-(1-diphenylmethylpiperidin-4-yl)-pentyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid
amide,

N-[6-(1-diphenylmethylpiperidin-4-yl)-hexyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid
amide,

N-[4-(4-phenyl-piperidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N- [4-(4,4-diphenyl-pipèridin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(1-benzoyl-2,6-dioxo-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,

N-[4-(2,6-dioxo-3-phenyl-piperidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(2,6-dioxo-4-phenyl-piperidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(4-benzoyl-piperazin-1-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,

N-[4-(4-benzoyl-piperazin-1-yl)-butyl]-3-(pyridin-3-yl)-propionamide,

N-[4-(4-diphenylacetyl-piperazin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(4-diphenylmethyl-piperazin-1-yl)-butyl]-3-pyridin-3-yl-propionamide,

N-[5-(4-diphenylmethyl-piperazin-1-yl)-pentyl]-3-pyridin-3-yl-acrylamide,

N-[6-(4-diphenylmethyl-piperazin-1-yl)-hexyl]-3-pyridin-3-yl-acrylamide,

N-[4-(4-diphenylmethyl-piperazin-1-yl)-butyl]-2-(pyridin-3-yl)-propionamide,

N-[4-(4-diphenylmethyl-piperazin-1-yl)-butyl]-5-(pyridin-3-yl)-penta-2,4-dienoic acid
amide, and

N-[4-(4-benzyi-2,6-dioxo-piperazin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide.


23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Currently Amended) A method of ~~treating a disease or medical condition~~ inhibiting or reducing angiogenesis in a mammal ~~which disease or medical condition responds to inhibition or reduction of~~ by inhibiting or reducing VEGF production, ~~said disease or medical condition being selected from rheumatoid arthritis, inflammatory disorder, macular degeneration, psoriasis, retinopathy, preneoplastic lesions, and hyperplasia,~~ said method comprising administering to said

administering to said mammal an effective amount of a compound of Formula I



I

or a pharmaceutically acceptable salt thereof,
wherein

A is selected from the group consisting of the group members C₁₋₁₀-alkylene, C₂₋₁₀-alkenylene, and C₂₋₁₀-alkynylene, which group members may be optionally substituted by one, two or three groups independently selected from C₁₋₃-alkyl, fluoro, chloro, and bromo;

R¹ is selected from hydrogen, C₁₋₆-alkyl, fluoro, chloro, bromo, and perfluoro-C₁₋₃-alkyl;

R² is selected from hydrogen, C₁₋₆-alkyl, and C₂₋₆-alkenyl; and

R³ is selected from the group consisting of the group members C₁₋₆-alkyl, (C₅₋₈-cycloalkyl)-C₁₋₆-alkyl, (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, C₁₋₆-alkyl (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, and C₁₋₅-alkylcarbonyl (C₅₋₈-heterocyclyl)-C₁₋₆-alkyl, which group members may be optionally substituted by one, two or three groups independently selected from C₁₋₆-alkyl, fluoro, chloro, bromo, oxo, perfluoro-C₁₋₃-alkyl, aryl, arylcarbonyl, heteroaryl, heteroarylcarbonyl, C₅₋₈-cycloalkyl and C₅₋₈-heterocyclyl.

27. (Withdrawn) A method of in vitro diagnosis of a disease or medical condition, which is selected from rheumatoid arthritis, inflammatory disorder, psoriasis, retinopathy, preneoplastic lesions, and hyperplasia, the method comprising obtaining a tumor from a warm blooded animal host, and implanting the tumor into mice to determine the decrease in growth after treatment with the compound of claim 15.

28. (Withdrawn) The method of claim 27, wherein the disease or medical condition is selected from proliferative retinopathy, diabetic retinopathy, benign prostatic hyperplasia, and venous neointimal hyperplasia.

29. (Currently Amended) A method of ~~treating or preventing a disease or medical condition~~ ~~which disease or medical condition is selected from rheumatoid arthritis, inflammatory disorder, macular degeneration, psoriasis, retinopathy, preneoplastic lesions, and hyperplasia,~~ inhibiting or reducing VEGF production in a human or animal, the method comprising administering a pharmaceutical composition to a human or animal in need thereof, wherein the pharmaceutical composition comprises one or more of the compounds of Formula I or a pharmaceutically acceptable salt thereof, as defined according to claim 15, optionally together with (a) pharmaceutically acceptable carrier(s), (a) toxicologically safe adjuvant(s), and/or in combination with other active ingredients.

30. (Cancelled)